Autologous Cord Blood Stem Cell Therapy
Pediatric Brain Injury / Infantile Cerebral Palsy
Phase 1Active
Key Facts
Indication
Pediatric Brain Injury / Infantile Cerebral Palsy
Phase
Phase 1
Status
Active
Company
About BrainRepair
BrainRepair is a pioneering biotech developing autologous cord blood stem cell therapies for pediatric brain injury, a condition that can lead to cerebral palsy. The company is clinically advanced, with its lead product having secured Orphan Drug Designation from the EMA and classification as an Advanced Therapy Medicinal Product - Tissue Engineered Product (ATMP-TEP). Its mission addresses a significant unmet medical need with no current curative treatments, positioning it at the forefront of regenerative medicine for neurological conditions in children.
View full company profile